Skip to main content
AAN.com

Abstract

The authors studied cognitive functioning as a potential predictor of survival in 68 newly diagnosed patients with high-grade glioma. In a combined Cox proportional hazards model, the influence of tumor, treatment, and patient characteristics, including cognitive functioning, was studied. Older age and higher tumor grade were associated with poorer survival. Although cognitive impairment was not found to be an independent prognostic factor for the entire sample, it was associated with significantly poorer survival among older patients with World Health Organization grade IV gliomas. Assessment of cognitive functioning in these patients may improve clinical decision making and thus quality of treatment.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int J Radiat Oncol Biol Phys. 1998; 40: 51–55.
2.
Devaux BC, O’Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. 1993; 78: 767–775.
3.
Curran WJ, Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 704–710.
4.
Thomas R, O’Connor AM, Ashley S. Speech and language disorders in patients with high grade glioma and its influence on prognosis. J Neurooncol. 1995; 23: 265–270.
5.
Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000; 18: 646–650.
6.
Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002; 20: 3445–3453.
7.
Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001; 19: 4037–4047.
8.
Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol. 1999; 52: 737–743.
9.
Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncol. 2003; 5: 89–95.

Information & Authors

Information

Published In

Neurology®
Volume 61Number 12December 23, 2003
Pages: 1796-1798
PubMed: 14694052

Publication History

Received: June 12, 2003
Accepted: August 20, 2003
Published online: December 22, 2003
Published in print: December 23, 2003

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

M. Klein, PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
T.J. Postma, MD PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
M.J.B. Taphoorn, MD PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
N.K. Aaronson, PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
W.P. Vandertop, MD PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
M. Muller, MSc
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
H.M. van der Ploeg, PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
J.J. Heimans, MD PhD
From the Departments of Medical Psychology (Drs. Klein and van der Ploeg), Neurology (Drs. Postma and Heimans), and Neurosurgery (Dr. Vandertop), VU University Medical Center, Amsterdam; Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht; and Division of Psychosocial Research & Epidemiology (Drs. Aaronson and Muller), The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Notes

Address correspondence and reprint requests to Dr. M. Klein, VU University Medical Center, Department of Medical Psychology, Van der Boechorststraat 7, 1081 BT Amsterdam, the Netherlands; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms, Frontiers in Oncology, 13, (2024).https://doi.org/10.3389/fonc.2023.1305725
    Crossref
  2. The relationship between social determinants of health and neurocognitive and mood-related symptoms in the primary brain tumor population: A systematic review, Neuro-Oncology Practice, 11, 3, (226-239), (2024).https://doi.org/10.1093/nop/npae016
    Crossref
  3. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition, Journal of Neuro-Oncology, 168, 1, (159-169), (2024).https://doi.org/10.1007/s11060-024-04646-x
    Crossref
  4. A Prospective Study of Longitudinal Risks of Cognitive Deficit for People Undergoing Glioblastoma Surgery Using a Tablet Computer Cognition Testing Battery: Towards Personalized Understanding of Risks to Cognitive Function, Journal of Personalized Medicine, 13, 2, (278), (2023).https://doi.org/10.3390/jpm13020278
    Crossref
  5. Real-Time Neuropsychological Testing (RTNT) and Music Listening during Glioblastoma Excision in Awake Surgery: A Case Report, Journal of Clinical Medicine, 12, 18, (6086), (2023).https://doi.org/10.3390/jcm12186086
    Crossref
  6. Therapy Resistance of Glioblastoma in Relation to the Subventricular Zone: What Is the Role of Radiotherapy?, Cancers, 15, 6, (1677), (2023).https://doi.org/10.3390/cancers15061677
    Crossref
  7. Triaxial accelerometer-measured physical activity and functional behaviours among people with High Grade Glioma: The BrainWear Study, PLOS ONE, 18, 5, (e0285399), (2023).https://doi.org/10.1371/journal.pone.0285399
    Crossref
  8. Extranodal lymphoma: pathogenesis, diagnosis and treatment, Molecular Biomedicine, 4, 1, (2023).https://doi.org/10.1186/s43556-023-00141-3
    Crossref
  9. Preoperative neurocognitive function as an independent survival prognostic marker in primary glioblastoma, Neuro-Oncology Practice, 10, 6, (527-535), (2023).https://doi.org/10.1093/nop/npad027
    Crossref
  10. How thought itself can drive tumour growth, Nature, 617, 7961, (469-471), (2023).https://doi.org/10.1038/d41586-023-01387-1
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share